Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10285822 | 1.00 | CHRNB4 (0.46) | CHRNB4CHRNA3 | |
| SCHEMBL5995159 | 1.00 | CHRNB4 (0.46) | CHRNB4CHRNA3 | |
| SCHEMBL15806843 | 0.94 | CYP1A2 (0.48) | CHRNB4CHRNA3 | |
| SCHEMBL25962289 | 0.94 | CYP1A2 (0.48) | CHRNB4CHRNA3 | |
| SCHEMBL2459458 | 0.89 | CHRNB4 (0.50) | CHRNB4CHRNA3 | |
| SCHEMBL20330340 | 0.87 | CHRNB4 (0.38) | CHRNB4CHRNA3 | |
| SCHEMBL9259241 | 0.82 | CYP1A2 (0.48) | — | |
| SCHEMBL13462239 | 0.82 | CHRNB4 (0.45) | CHRNB4CHRNA3 | |
| SCHEMBL7798503 | 0.82 | CHRNB4 (0.45) | CHRNB4CHRNA3 | |
| SCHEMBL18455133 | 0.80 | CHRNB4 (0.47) | CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024086730-A1 | HETEROCYCLIC CBL-B INHIBITORS FOR THE TREATMENT OF CANCER | HOTSPOT THERAPEUTICS, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| WO-2023116779-A1 | DIALKYNE COMPOUND AND USE THEREOF | 上海艾力斯医药科技股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| US-20090131436-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
| WO-2007128568-A1 | BICYCLIC DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131436-A1 | Pyrimidine Derivatives | DPYD, TYMP, TYMS | CHRNB4 4329/4885CHRNA3 4401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.